Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Indium-111-pentetreotide, a radiolabeled somatostatin analog, has been proposed for imaging tumors bearing somatostatin receptors. This study evaluates the safety, efficacy and impact on patient management of this scintigraphic agent in patients with gastroenteropancreatic (GEP) neuroendocrine tumors.


METHODS
We studied 47 consecutive patients with a proven or clinically suspected GEP neuroendocrine tumor who were imaged 4 and 24 hr after injection of 111In-pentetreotide. The patients were monitored for adverse reactions and changes in vital signs or clinical chemistry over 24 hr. The scintigraphic findings were compared with results from conventional imaging methods. The patients were followed over a minimal 6-mo period during which further localization procedures were performed to confirm or refute the additional tumor sites found at scintigraphy.


RESULTS
No adverse reactions or clinically relevant changes in clinical chemistry were noted after injection of the radiopharmaceutical. The final diagnosis of a GEP neuroendocrine tumor was retained in 38 patients. Somatostatin receptor-positive lesions were found in 33 of these patients, whereas conventional methods were positive in 31 patients. Of the 54 sites seen by conventional procedures, 50 sites were also detected scintigraphically.


CONCLUSIONS
Indium-111-pentetreotide is a safe, sensitive imaging agent in the detection of GEP neuroendocrine tumor sites. Indium-111-pentetreotide also provides information on the somatostatin receptor status of the tumor and may therefore aid in therapeutic decisions.
Jamar
F
F
Department of Nuclear Medicine, University of Louvain Medical School, Brussels, Belgium.
Fiasse
R
R
Leners
N
N
Pauwels
S
S
D005260:Female; D005770:Gastrointestinal Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D007205:Indium Radioisotopes / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000628:therapy; D011446:Prospective Studies; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000032:analysis*; D012449:Safety; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives*
D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013004:Somatostatin; C081788:pentetreotide